|
IL139400A0
(en)
*
|
2000-11-01 |
2001-11-25 |
Yeda Res & Dev |
Long-acting cytokine derivatives and pharmaceutical compositions comprising them
|
|
AU2002239384B2
(en)
*
|
2000-12-13 |
2007-01-11 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
PL211116B1
(pl)
|
2001-10-19 |
2012-04-30 |
Idexx Lab |
Komozycja do podawania ssakowi związku farmakologicznie czynnego i sposób wytwarzania preparatu do wstrzyknięć
|
|
US6946137B2
(en)
*
|
2001-10-19 |
2005-09-20 |
Idexx Laboratories, Inc. |
Methods for the controlled delivery of pharmacologically active compounds
|
|
US20030171285A1
(en)
*
|
2001-11-20 |
2003-09-11 |
Finn Rory F. |
Chemically-modified human growth hormone conjugates
|
|
BE1015608A6
(fr)
*
|
2003-07-15 |
2005-06-07 |
Messadek Jallal |
Traitement des arterites.
|
|
JP4033382B2
(ja)
*
|
2002-04-08 |
2008-01-16 |
久光製薬株式会社 |
インスリン投与装置
|
|
EP1583972B1
(en)
*
|
2003-01-16 |
2010-11-24 |
caprotec bioanalytics GmbH |
Methods for identifying drug non-target proteins
|
|
WO2004089280A2
(en)
*
|
2003-04-08 |
2004-10-21 |
Yeda Research And Development Co. Ltd. |
Reversible pegylated drugs
|
|
EP1615632B1
(fr)
*
|
2003-04-17 |
2006-12-06 |
Jallal Messadek |
Formulations orales flottantes pour la liberation controlee de la betaine
|
|
AU2004261353B2
(en)
|
2003-08-05 |
2009-12-10 |
Novo Nordisk A/S |
Novel insulin derivatives
|
|
BE1016128A6
(fr)
*
|
2004-07-22 |
2006-03-07 |
Messadek Jallal |
Combinaisons therapeutiques
|
|
US7282487B2
(en)
*
|
2004-10-28 |
2007-10-16 |
Idexx Laboratories |
Method for treating bacterial infections in horses or pigs with tilmicosin
|
|
WO2006050581A2
(en)
*
|
2004-11-10 |
2006-05-18 |
Jallal Messadek |
Betaine as agent against arthropod - or mosquito -borne diseases
|
|
RU2007143510A
(ru)
*
|
2005-04-27 |
2009-06-10 |
Яллал МЕССАДЕК (BE) |
Инсулиновые композиции
|
|
EP1969004B1
(en)
|
2005-12-28 |
2011-08-10 |
Novo Nordisk A/S |
Compositions comprising an acylated insulin and zinc and method of making the said compositions
|
|
JP5552046B2
(ja)
|
2007-06-13 |
2014-07-16 |
ノボ・ノルデイスク・エー/エス |
インスリン誘導体を含有する薬学的製剤
|
|
WO2009065193A1
(en)
*
|
2007-11-21 |
2009-05-28 |
Jallal Messadek |
Treatment of aspirin resistance with betaine and/or betaine enriched molasses
|
|
HUE032284T2
(en)
|
2008-03-18 |
2017-09-28 |
Novo Nordisk As |
Protease-stabilized, acylated insulin analogues
|
|
CN102076331B
(zh)
|
2008-06-26 |
2013-12-18 |
普罗林科斯有限责任公司 |
具有可控的药物释放速率的前药和药物-大分子轭合物
|
|
EP2344200A2
(en)
*
|
2008-09-19 |
2011-07-20 |
Nektar Therapeutics |
Modified therapeutics peptides, methods of their preparation and use
|
|
EP2350118B1
(en)
*
|
2008-09-19 |
2016-03-30 |
Nektar Therapeutics |
Carbohydrate-based drug delivery polymers and conjugates thereof
|
|
JP5775820B2
(ja)
*
|
2008-10-21 |
2015-09-09 |
バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated |
遊離可能peg試薬を有するプロドラッグpegタンパク質結合体において活性成分(インビトロ脱ペグ化)を決定する方法
|
|
CN102202683A
(zh)
|
2008-10-30 |
2011-09-28 |
诺沃-诺迪斯克有限公司 |
用少于每日一次的注射频率注射胰岛素来治疗糖尿病
|
|
CN102413843A
(zh)
|
2009-03-05 |
2012-04-11 |
阿森迪斯药物股份有限公司 |
干扰素α载体前药
|
|
WO2011013128A2
(en)
|
2009-07-31 |
2011-02-03 |
Yeda Research And Development Co. Ltd. |
Vectors for delivery of neurotherapeutics to the central nervous system
|
|
WO2011140393A1
(en)
*
|
2010-05-05 |
2011-11-10 |
Prolynx Llc |
Controlled release from macromolecular conjugates
|
|
DK2632478T3
(da)
|
2010-10-27 |
2019-10-07 |
Novo Nordisk As |
Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
|
|
EP2490378B1
(en)
|
2011-02-18 |
2014-07-09 |
NTT DoCoMo, Inc. |
Apparatus and method for determining a control unit using feasibility requests and feasibility responses
|
|
EP2714070B1
(en)
|
2011-06-02 |
2024-03-20 |
OPKO Biologics Ltd. |
Long-acting glp-1/glucagon receptor agonists
|
|
US10166295B2
(en)
|
2011-06-02 |
2019-01-01 |
Opko Biologics Ltd. |
Pegylated OXM variants
|
|
EP2836508B1
(en)
|
2012-04-11 |
2016-06-29 |
Novo Nordisk A/S |
Insulin formulations
|
|
MX362432B
(es)
|
2012-06-04 |
2019-01-17 |
Opko Biologics Ltd |
Variantes de oxm pegilada.
|
|
WO2014009316A1
(en)
|
2012-07-09 |
2014-01-16 |
Novo Nordisk A/S |
Novel use of insulin derivatives
|
|
EP2991672A1
(en)
|
2013-04-30 |
2016-03-09 |
Novo Nordisk A/S |
Novel administration regime
|
|
ES2886837T3
(es)
|
2016-12-16 |
2021-12-21 |
Novo Nordisk As |
Composiciones farmacéuticas que contienen insulina
|
|
US10335464B1
(en)
|
2018-06-26 |
2019-07-02 |
Novo Nordisk A/S |
Device for titrating basal insulin
|
|
US12441776B2
(en)
|
2018-11-30 |
2025-10-14 |
Eirgen Pharma Ltd. |
Oxyntomodulin peptide analog formulations
|
|
US20200254065A1
(en)
|
2019-02-11 |
2020-08-13 |
Opko Biologics Ltd. |
Long-acting glp-2 analogs
|
|
CN114096269B
(zh)
|
2019-07-12 |
2024-06-11 |
诺和诺德股份有限公司 |
高浓度胰岛素制剂
|
|
WO2021067458A1
(en)
|
2019-09-30 |
2021-04-08 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Protein-macromolecule conjugates and methods of use thereof
|
|
CN113773398B
(zh)
*
|
2020-06-10 |
2023-05-23 |
宁波鲲鹏生物科技有限公司 |
一种德谷胰岛素衍生物及其应用
|
|
CN117551008B
(zh)
*
|
2023-11-10 |
2025-10-17 |
沈阳药科大学 |
一种去铁胺偶联物及其制备方法和应用
|